

Supplementary Table 4. Cumulative incidence function for major gastrointestinal bleeding after stroke (n=10,818)

Intervals after the onset of index stroke	Cumulative incidence function (95% CI), %
1 Week	0.70 (0.62–1.02)
1 Month	1.56 (1.35–1.81)
3 Months	2.83 (2.53–3.15)
1 Year	5.03 (4.63–5.45)
2 Years	6.93 (6.47–7.41)
3 Years	8.30 (7.78–8.83)

Cumulative incidence function was estimated for competing risk data. Death was a competing event for major gastrointestinal bleeding event. CI, confidence interval.

Supplementary Table 5. Incidence rates of major GI bleeding in patients with acute ischemic stroke according to the elapsed time since stroke onset and predefined subgroups of antithrombotics at discharge

Antithrombotics at discharge	Intervals after the onset of index stroke						
	≤1 month	2–3 months	4–6 months	7–12 months	2nd year	3rd year	>3 years
ASA mono	12.2 (8.9–16.7)	5.7 (4.1–8.0)	5.0 (3.8–7.0)	2.0 (1.5–2.8)	2.2 (1.7–2.7)	1.8 (1.4–2.4)	1.5 (1.0–2.1)
Other AP mono	42.5 (29.2–62.0)	8.9 (4.9–16.1)	10.1 (6.3–16.0)	3.1 (1.7–5.6)	4.5 (3.2–6.5)	1.9 (1.0–3.5)	4.1 (2.6–6.6)
Clopidogrel	31.8 (18.8–53.6)	5.8 (2.4–13.9)	7.9 (4.3–14.7)	2.0 (0.8–4.8)	4.6 (3.0–7.0)	2.4 (1.2–4.6)	3.3 (1.8–6.1)
Cilostazol	81.8 (44.0–152.1)	21.8 (9.1–52.4)	24.8 (12.4–49.5)	6.5 (2.4–17.3)	4.5 (1.9–10.8)	1.1 (0.2–7.7)	4.2 (1.4–13.2)
Others	41.4 (13.4–128.4)	7.2 (1.0–51.2)	0	5.1 (1.3–20.5)	4.3 (1.4–13.3)	0	8.4 (3.5–20.1)
Dual AP or more	17.3 (13.0–23.0)	9.1 (6.8–12.0)	4.3 (3.0–6.0)	3.7 (2.8–4.8)	2.8 (2.2–3.5)	2.5 (2.0–3.3)	2.5 (1.9–3.4)
Aspirin+clopidogrel	17.3 (12.6–23.8)	8.9 (6.5–12.2)	4.6 (3.2–6.7)	4.0 (3.0–5.3)	2.7 (2.1–3.5)	2.9 (2.2–3.8)	2.8 (2.1–3.9)
Aspirin+cilostazol	16.6 (7.9–34.7)	9.6 (4.8–19.3)	2.5 (0.8–7.6)	2.4 (1.1–5.4)	3.1 (1.8–5.2)	1.1 (0.4–3.0)	1.2 (0.4–3.8)
Others	19.3 (4.8–77.0)	9.9 (2.5–39.8)	3.5 (0.5–24.6)	1.7 (0.2–12.4)	2.8 (0.9–8.5)	1.1 (0.2–7.7)	1.1 (0.2–7.7)
AC without AP	9.6 (5.6–16.6)	11.2 (7.8–16.1)	9.1 (6.5–12.7)	4.9 (3.5–6.8)	3.5 (2.6–4.7)	4.4 (3.3–5.9)	4.9 (3.5–6.8)
Warfarin	7.9 (4.3–14.8)	10.3 (6.9–15.2)	8.8 (6.2–12.5)	4.8 (3.4–6.8)	3.4 (2.5–4.5)	4.4 (3.3–6.0)	4.9 (3.5–6.8)
NOAC	0	14.6 (2.1–103.4)	10.0 (1.4–71.1)	5.3 (0.8–37.8)	3.0 (0.4–21.2)	6.6 (0.9–46.6)	0
Others	44.6 (14.4–138.1)	34.5 (12.9–91.8)	19.1 (6.2–59.3)	7.5 (1.9–29.9)	6.7 (2.2–20.7)	0	9.6 (1.4–68.2)
AC with AP	18.9 (9.4–37.7)	13.6 (7.5–24.6)	10.6 (6.0–18.6)	6.9 (4.2–11.5)	5.7 (3.7–8.6)	2.6 (1.3–5.2)	3.8 (1.9–7.7)
No treatment	83.0 (59.3–116.2)	24.7 (15.6–39.3)	9.0 (4.7–17.4)	7.5 (4.5–12.7)	6.0 (3.8–9.3)	2.3 (1.0–5.2)	2.2 (0.8–6.0)

Values presented are incidence rates (95% confidence intervals).

GI, gastrointestinal; ASA, aspirin; AP, antiplatelets; AC, anticoagulants; NOAC, non-vitamin K antagonist oral anticoagulants.